tetano
Editor, Senior Moderator
Best Pract Res Clin Haematol
. 2022 Sep;35(3):101382.
doi: 10.1016/j.beha.2022.101382. Epub 2022 Sep 7.
COVID-19 outcomes in sickle cell disease and sickle cell trait
Jana Christian[SUP] 1 [/SUP], Sophie Lanzkron[SUP] 1 [/SUP], Rakhi P Naik[SUP] 2 [/SUP]
Affiliations
Abstract
Throughout the Coronavirus Disease 2019 (COVID-19) pandemic, understanding the effects of COVID-19 on persons with Sickle Cell Disease (SCD) and Sickle Cell Trait (SCT) has garnered interest. Patients with SCD diagnosed with COVID-19 utilize the emergency department and are hospitalized at significantly higher rates compared to the general population, with vaso-occlusive crisis and acute chest syndrome as the leading presentations. Whether SCD alone increases the likelihood of severe COVID-19 illness remains uncertain; however, potential risk factors for severe disease among patients with SCD include older age, frequent acute care visits for pain, haemoglobin SC disease, and pre-existing end-organ disease. SCT status may also influence COVID-19 outcomes, particularly among those with pre-existing co-morbidities. Corticosteroids in patients with SCD and COVID-19 should be used with extreme caution given strong associations between corticosteroid exposure and severe vaso-occlusive crisis, with prophylactic transfusion administered if corticosteroids are deemed necessary. Hydroxyurea may be protective in COVID-19.
. 2022 Sep;35(3):101382.
doi: 10.1016/j.beha.2022.101382. Epub 2022 Sep 7.
COVID-19 outcomes in sickle cell disease and sickle cell trait
Jana Christian[SUP] 1 [/SUP], Sophie Lanzkron[SUP] 1 [/SUP], Rakhi P Naik[SUP] 2 [/SUP]
Affiliations
- PMID: 36494153
- DOI: 10.1016/j.beha.2022.101382
Abstract
Throughout the Coronavirus Disease 2019 (COVID-19) pandemic, understanding the effects of COVID-19 on persons with Sickle Cell Disease (SCD) and Sickle Cell Trait (SCT) has garnered interest. Patients with SCD diagnosed with COVID-19 utilize the emergency department and are hospitalized at significantly higher rates compared to the general population, with vaso-occlusive crisis and acute chest syndrome as the leading presentations. Whether SCD alone increases the likelihood of severe COVID-19 illness remains uncertain; however, potential risk factors for severe disease among patients with SCD include older age, frequent acute care visits for pain, haemoglobin SC disease, and pre-existing end-organ disease. SCT status may also influence COVID-19 outcomes, particularly among those with pre-existing co-morbidities. Corticosteroids in patients with SCD and COVID-19 should be used with extreme caution given strong associations between corticosteroid exposure and severe vaso-occlusive crisis, with prophylactic transfusion administered if corticosteroids are deemed necessary. Hydroxyurea may be protective in COVID-19.